Table 2.

Mean dose in patients with NSCLC included in the MONITOR‐GCSF study

Patient group	Mean dose (µg)	Median dose (min, max)	Discontinued prophylaxis, n (%)
All patients (n = 341)	6,962.0	6,000 (480; 40,320)	65 (19.1) [15.25%; 23.57%]
≥65 years of age (n = 142)	6,069.3	4,800 (480; 31,680)	27 (19.0) [13.41%; 26.25%]
≥70 years of age (n = 81)	5,820.0	4,500 (480; 31,680)	14 (17.3) [10.58%; 26.95%]